> 首页 > 产品 > 一抗 > 其他 > Anti-Factor IX & Factor X Reference Antibody (Emicizumab)

Anti-Factor IX & Factor X Reference Antibody (Emicizumab)

Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) is 100.00%, determined by SEC-HPLC.
Emicizumab bound to Factor IX protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Emicizumab bound in human Factor IX Protein-His, and the EC50 was 2.296 nM.
Emicizumab bound to Factor X protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Emicizumab bound in human Factor X Protein-His, and the EC50 was 2.033 nM.
The detected molecular weight of Anti-Factor IX & Factor X Reference Antibody (Emicizumab) is 145.60 kDa.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P00740 & P00742
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-like

Additional Information
Target/Specificity	F9 / Factor IX,Factor X / FXa
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.